Jafron Biomedical Co.,Ltd. (SHE:300529)

Market Cap	20.38B
Revenue (ttm)	2.63B
Net Income (ttm)	804.47M
Shares Out	774.36M
EPS (ttm)	1.01
PE Ratio	26.00
Forward PE	18.76
Dividend	0.40 (1.52%)
Ex-Dividend Date	May 31, 2024

Volume	7,561,425
Average Volume	7,441,730
Open	25.79
Previous Close	26.64
Day's Range	25.79 - 26.88
52-Week Range	21.83 - 39.24
Beta	0.45
RSI	50.93
Earnings Date	Apr 16, 2025

About Jafron Biomedical

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption field in worldwide. The company provides solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases. It offers HA series hemoperfusion cartridge, BS series bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, disinfectants, hemodialysis co...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,408
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2023, Jafron Biomedical's revenue was 1.92 billion, a decrease of -22.84% compared to the previous year's 2.49 billion. Earnings were 436.49 million, a decrease of -50.93%.